专利检索 ap:("INSERM (Institut National de la Santé et de la Recherche Médicale)" OR "Université Paul Sabatier Toulouse III" OR "Icahn School of Medicine at Mount Sinai") AND inv:"Malik BISSERIER" 第 1 页

1.

发明申请
EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS 有权

公开(公告)号：US20230030517A1

公开(公告)日：2023-02-02

申请号：US17783928

申请日：2020-12-11

申请人： INSERM (Institut National de la Santé et de la Recherche Médicale) , Université Paul Sabatier Toulouse III , Icahn School of Medicine at Mount Sinai

发明人： Malik BISSERIER , Frank LEZOUALC'H , Lahouaria HADRI

IPC分类号： A61K31/4365 , A61K31/47 , A61P11/00

摘要： The present invention relates to the treatment of idiopathic pulmonary fibrosis. Today, there is no cure for IFF. The inventors showed that EPAC1 inhibitors, in particular CE3F4 and AM-001, represent a promising therapeutic strategy for treating patients with pulmonary fibrosis. The present invention thus relates to an EPAC1 inhibitor for use in the treatment and/or prevention of idiopathic pulmonary fibrosis.

2.

发明申请
TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS EPAC1 INHIBITORS FOR THE TREATMENT OF MYOCARDIAL INFARCTION INJURY 审中-公开

公开(公告)号：US20170079970A1

公开(公告)日：2017-03-23

申请号：US15126312

申请日：2015-03-20

申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , UNIVERSITÉ PAUL SABATIER TOULOUSE III

发明人： Frank LEZOUALC'H , Pierre SICARD , Malik BISSERIER

IPC分类号： A61K31/47 , A61K45/06

CPC分类号： A61K31/47 , A61K45/06 , A61K2300/00

摘要： The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a method for providing cardioprotection in a subject who experienced a myocardial infarction comprising administering the subject with a therapeutically effective amount of at least one EPAC1 inhibitor.